About the Study
CaRISMA is a large national study we conducted to explore non-drug approaches to managing chronic pain and mental health in sickle cell disease (SCD). We designed a mobile app to compare two different approaches that are affordable, easily accessible, and effective. We wanted to know which method works better for what kinds of individuals.
Background
The hidden battle – living with sickle cell disease and chronic pain.
Purpose/Goal
Digital CBT vs. digital education
The study can potentially improve pain management in routine SCD care and address the healthcare disparities experienced by low-income, low-resourced, and minority groups.
About Sickle Cell Disease
Sickle cell disease is a complex genetic disorder that affects millions of people worldwide. It often involves chronic pain, healthcare disparities, and emotional stress. Our study recognizes these challenges and seeks to address them comprehensively.
It is important to consider the impact of SCD on mental health.
Although many people with SCD experience symptoms of depression, and even more may have anxiety, mental health is often not considered for patients with SCD.
The study compared the effectiveness of the two mobile phone-delivered programs in reducing SCD pain symptoms: digital CBT vs. digital education.
The comparison between the two programs is based on their approach to teaching coping skills. The digital CBT program teaches skills through practical experience by “seeing and doing,” while the digital education program teaches skills through education by “learning and knowing” – teaching users about chronic pain, healthy lifestyle habits (e.g., nutrition and exercise), and facts about SCD.
The study aimed to determine which approach is more effective.
The image shows a visual of how CBT and education can help people living with SCD.
Study Closure:
As of May 1, the CaRISMA Study is officially closed with 359 participants. This exceeded or roll of 350 participants. We are immensely grateful for the trust and dedication of the individuals who participated, the healthcare professionals who supported us, and the community that rallied behind this initiative.
Results Coming in Fall 2023
We understand that many have been eagerly anticipating the results of this study. We are excited to announce that the findings will be made public in the Fall of 2023. This research represents a significant step forward in understanding the potential benefits of Cognitive Behavioral Therapy (CBT) for individuals living with sickle cell disease.
What to expect
In the coming months, we will be meticulously analyzing the data collected throughout the study. Our goal is to provide a comprehensive and informative report that not only outlines the outcomes but also offers insights into how CBT can impact the lives of those with sickle cell disease.
Stay Updated
To ensure you receive the latest information about the study results, please follow us on social media. We will be sharing updates, release dates, and opportunities to engage with our findings in the lead-up to the Fall 2023 release.
Thank You
Once again, we extend our deepest gratitude to all who have been a part of this journey. Your participation and support have been invaluable, and we look forward to sharing the study’s results with you.
If you have any immediate questions or require further information, please feel free to reach out to us at dhendricks@pitt.edu.
Thank you for being a part of this important endeavor. We are excited to unveil the study results and continue our commitment to improving the lives of individuals living with sickle cell disease.
